Vaccins et dispositifs d'administration

teste

Auteur: Alex Adjagba

MCV 5-dose vial assessment support tool

Auteur: Linksbridge

Leveraging micro-array patch (MAP) technology for vaccine delivery - TechNet Conference 2023

Auteur: Anna-Lea Kahn, Courtney Jarrahian, Jennifer Foster, Shan Hsu

WHO news release - R21/Matrix-M malaria vaccine recommendation

Auteur: World Health Organization (WHO)

WHO prequalification - Mosquirix (RTS,S/AS01)

Auteur: World Health Organization (WHO)

Malaria vaccine - questions and answers

Auteur: World Health Organization (WHO)

Full evidence report on the R21/Matrix-M malaria vaccine

Auteur: World Health Organization (WHO)

Full evidence report on the RTS,S/AS01 malaria vaccine

Auteur: World Health Organization (WHO)

WHO Guidelines for malaria

Auteur: World Health Organization (WHO)

WHO vaccine position papers and guidance on Malaria

Auteur: World Health Organization (WHO)

The effects of switching from 10 to 5-dose vials of MR vaccine on vaccination coverage and wastage: A mixed-method study in Zambia

Auteur: Natasha Kanagat, Ali Karim, Robert Steinglass, Barbara Knittel, Frances Mwansa, Kirstin Krudwig, Guissimon Phiri, Wendy Prosser

Gavi Product Menu

Auteur: UNICEF

UNICEF Pricing Information-MCV

Auteur: UNICEF

UNICEF Pricing Information-MMR

Auteur: UNICEF

UNICEF Pricing Information-MR

Auteur: UNICEF

UNICEF Pricing Information-HPV

Auteur: UNICEF

UNICEF Pricing Information-RVV

Auteur: UNICEF

UNICEF Pricing Information-PCV

Auteur: UNICEF

Acceptability and feasibility of delivering pentavalent vaccines in a compact, prefilled, autodisable device in Vietnam and Senegal

Auteur: Phan Dang Than, Fatoumata Hane, Tran Van Dinh, Seydina Ousmane Ba, Hamadou M DICKO, Philippe Jaillard, Khadidjatou Gomis, Elise Guillermet, Bradford D. Gessner, Nguyen Thi Thi Tho, Le Thi Phuong Mai, Anais Colombini, Nguyen Thi Phuong Lien, Mamadou N’Diaye

Vaccine adjuvants

Auteur: Fox et al.

Experience and challenges from clinical trials with malaria vaccines in Africa

Auteur: Marcel Tanner, Tutu Mzee, Salim Abdulla, Nahya Salim, Shubis Kafuruki, Grace Mwangoka, Maxmillian Mpina, Bernhards Ogutu, Seif Shekalaghe, Beverly Msambichaka,

Sudden unexpected deaths and vaccinations during the first two years of life in italy: A case series

Auteur: Giuseppe Traversa, Roberto Raschetti, Stefania Spila-Alegiani, Stefania Salmaso, Clara Bianchi, Gianpaolo Scalia Tomba, Marta Ciofi degli Atti, Luisa Frova, , Marco Massari

Efficacy, immunogenicity, and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period

Auteur: Robert M. Jacobson, D. Bruce Burlington, George E. Armah, Leonard P. Ruiz, Albert Z. Kapikian, Timo Vesikari, Nigel Cunliffe

Immunogenicity, safety, and tolerability of a hexavalent vaccine in infants

Auteur: Sheryl A. Flores, Andrew W. Lee, Angela L. Ngai, Gary S. Marshall, Jin Xu, Gregory L. Adams, Guanghan Liu, Michael L. Leonardi, Jon E. Stek, Maria Petrecz, Ginamarie Foglia

Immunogenicity and estimation of antibody persistence following vaccination with an inactivated virosomal hepatitis A vaccine in adults: A 20-year follow-up study

Auteur: François Chappuis, Coby Stals, Tiziana Farinelli, Henri Deckx, Michal Sarnecki, Oscar Go, Yvonne Salzgeber

Safety and immunogenicity of two doses of quadrivalent meningococcal conjugate vaccine or one dose of meningococcal group C conjugate vaccine, both administered concomitantly with routine immunization to 12- to 18-month-old children

Auteur: Philipp Oster, Francisco Noya, Deirdre McCormack, Donna L. Reynolds, Dion Neame

Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial

Auteur: Anisur Rahman, Mohammad Ali, Taufiqur R. Bhuiyan, Farzana Begum, Fahima Chowdhury, Ashraf Uddin Siddik, Shah Alam Siddique, Mohiul Islam Chowdhury, Leanne Unicomb, Ashraful Islam Khan, Nirod Chandra Saha, Muhammad Asaduzzaman, Jasim Uddin, Stephen P. Luby, Amit Saha, Alamgir Kabir, Afroza Akter, Jahangir A.M. Khan, Alejandro Cravioto, Iqbal Ansary Khan, Baizid Khoorshid Riaz, Arifuzzaman Khan, Atique Iqbal Chowdhury, John D. Clemens, Yasmin A. Begum, Shwapon Kumar Biswas, Young Ae You, Firdausi Qadri

Efficacy of a single-dose, inactivated oral cholera vaccine in Bangladesh

Auteur: Ashraf U. Siddik, M.Med , Atique I. Chowdhury, Thomas F Wierzba, John D. Clemens, Yasmin A. Begum, Nirod C Saha, Iqbal A. Khan, Anisur Rahman, Mohammad Ali, Taufiqur R. Bhuiyan, Alamgir Kabir, Muhammad Asaduzzaman, Shah A. Siddique, Fahima Chowdhury, Farhana Khanam, Alejandro Cravioto, M.Phil, Young A. You, Ashraful I. Khan, Mohiul I. Chowdhury, Sachin N Desai, Afroza Akter, Deok R. Kim, Amit Saha, Taufiqul Islam, Firdausi Qadri, Ajit P. Singh, Arifuzzaman Khan

Comparative tuberculosis (TB) prevention effectiveness in children of Bacillus Calmette-Guérin (BCG) vaccines from different sources, Kazakhstan

Auteur: Indira Aitmagambetova, Paul Kilgore, Shakhimurat Ismailov, Michael Favorov, Terence Chorba, Mohammad Ali, Aigul Tursunbayeva

Hepatitis B virus infection in northern Uganda: Impact of pentavalent hepatitis B vaccination

Auteur: Robert Downing, Eyasu H. Teshale, Saleem Kamili, Jan Drobeniuc, Maxine Denniston, Barnabas Bakamutamaho

Risk in vaccine research and development quantified

Auteur: Albertus D. M. E. Osterhaus, Esther S. Pronker, Tamar C. Weenen, Harry Commandeur, Eric H. J. H. M. Claassen

Intussusception risk after RotaTeq vaccination: evaluation from worldwide spontaneous reporting data using a self-controlled case series approach

Auteur: Catherine Hill, Pascale Tubert-Bitter, Sylvie Escolano

Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines

Auteur: Sohail Ahmed, Rino Rappuoli, Steven Black, Ernesto Oviedo-Orta

Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study

Auteur: Sepehr N. Tabrizi, Matthew G. Law, Catriona S. Bradshaw, Eric P. F. Chow, Suzanne M Garland, Jennifer A. Danielewski, Marcus Y. Chen, Glenda Fehler, Christopher K. Fairley

Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children

Auteur: Corinne Levy, Emmanuelle Varon, Robert Cohen, Stéphane Béchet, Catherine Doit

Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders

Auteur: Richard T. Mahoney, Ole Wichmann, Don L. Douglas, Denise A. DeRoeck

Innovation partnership for a roadmap on vaccines in Europe (IPROVE): A vision for the vaccines of tomorrow

Auteur: Magdalena R De Azero, Odile Leroy, Florence Bietrix, Philippe Denoel, Donata Medaglini

Disparate adjuvant properties among three formulations of “alum”

Auteur: Derek W. Cain, Sergio E. Sanders, Michael M. Cunningham, Garnett Kelsoe

An evaluation of emerging vaccines for childhood meningococcal disease

Auteur: Hope L. Johnson, Evropi Theodoratou, Igor Rudan, Jian Shayne F. Zhang, Harish Nair, Shams El Arifeen, Lina Zgaga, Christopher B. Nelson, Rachel Falconer, Debajeet Choudhuri, Ray Borrow, Ivana Luksic, Tanvir Huda, Harry Campbell

High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses

Auteur: William C. Weldon, Christiana Agyei-Yeboah, Oberste, Jonathan C. J. Wei, Paul R. Young, Alexandra C. I. Depelsenaire, David A. Muller, Mark A. F. Kendall, Angus Forster, Germain J. P. Fernando, Paul Fahey, Nick S. Owens

Exploring new packaging and delivery options for the immunization supply chain

Auteur: Darin Zehrung, Courtney Jarrahian, Birgitte Giersing, Debra Kristensen

Use of oral cholera vaccines in an outbreak in Vietnam: A case control study

Auteur: Shannon L. Grahek, Nguyen Tran Hien, Vu Dinh Thiem, Michael Favorov, Anna Lena Lopez, Hye Jung Kwon, Dang Duc Anh, Jin Kyung Park, Tran Nhu Duong, John D. Clemens

OPTIMIZAÇÃO DO ESQUEMA DE VACINAÇÃO ANTI-VPH Principais considerações para a tomada de decisões, a programação e a implementação

OPTIMIZACIÓN DEL ESQUEMA DE LA VACUNA CONTRA EL VPH Aspectos clave para la toma de decisiones, planificación e implementación

HPV VACCINE SCHEDULE OPTIMIZATION Key considerations for decision-making, planning, and implementation

Auteur: PATH, JSI, UNICEF, Gavi, the Vaccine Alliance, World Health Organization (WHO)

OPTIMISATION DU SCHÉMA DE VACCINATION ANTI-VPH Principales considérations en matière de prise de décision, de planification et de mise en œuvre

HPV VACCINE SCHEDULE OPTIMIZATION — KEY CONSIDERATIONS FOR DECISION-MAKING, PLANNING AND IMPLEMENTATION

ОПТИМИЗАЦИЯ СХЕМЫ ИММУНИЗАЦИИ ПРОТИВ ВПЧ - ОСНОВНЫЕ МОМЕНТЫ, НА КОТОРЫЕ НЕОБХОДИМО ОБРАТИТЬ ВНИМАНИЕ ПРИ ПРИНЯТИИ РЕШЕНИЙ, ПЛАНИРОВАНИИ И

How to use a bifurcated needle to perform multiple puncture vaccination technique

Auteur: World Health Organization (WHO)

DTaP-IPV-Hep B-Hib Vaccine (Hexaxim(®)): a review of its use in primary and booster vaccination

Auteur: Paul L. McCormack

Pertussis vaccines: WHO position paper, August 2015-Recommendations.

Auteur: World Health Organization (WHO)

Hepatitis B vaccine in healthy hospital employees

Auteur: R. Normand, S. A. Klotz, R. Silberman

Study Demonstrates Benefit of West's ID Adapter for Improving Intradermal Administration of Polio Vaccine

Auteur: West Pharmaceutical Services, Inc.

Overview of clinical trials and developments with the inactivated vaccine against Japanese encephalitis

Auteur: Tomas Jelinek

Applying mathematical tools to accelerate Vaccine Development: modeling shigella immune dynamics

Auteur: Marcelo B. Sztein, Doron Levy, Courtney L. Davis, Rezwanul Wahid, Franklin R. Toapanta, Jakub K. Simon

Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability

Auteur: Dexiang Chen, LaToya Jones Braun, Tanya Clapp, Paul Siebert

Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases

Auteur: Claire M. Tully, Teresa Lambe, Sarah C. Gilbert, Adrian V. S. Hill

Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions

Auteur: Steven G. Reed, Thomas S. Vedvick, Christopher B. Fox, Susan L. Baldwin, Malcolm S. Duthie

Indian vaccine innovation: the case of Shantha Biotechnics

Auteur: Kumar Perampaladas, Jennifer Heys, Peter A. Singer, Justin Chakma, Hassan Masum

Comparison of hepatitis B vaccine coverage and effectiveness among urban and rural Mongolian 2-year-olds

Auteur: Pagbajabyn Nymadawa, Nyamkhuu Dulmaa, James S. Edstam, Ann Marie Kimball, J. Khulan, Arslan Rinchin

Demographic Health Survey (DHS), Multiple Indicators Cluster Survey (MICS)

Auteur: UNICEF

Accurate prediction of vaccine stability under real storage conditions and during temperature excursions

Auteur: Didier Clénet

Performance and potency of tetanus toxoid: implications for eliminating neonatal tetanus

Auteur: V. Dietz, J. B. Milstien, F. van Loon, S. Cochi, J. Bennett

Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines

Auteur: Christina Ann Boros, D. M. Roberton, Michael Steven Gold, M. Hanlon

A novel single-dose dengue subunit vaccine induces memory immune responses

Auteur: Yi-Shiuan Li, Hsin-Wei Chen, Jy-Ping Tsai, Chih-Hsiang Leng, Shih-Jen Liu, Pele Chong, Chen-Yi Chiang, Hsueh-Hung Liu, Mei-Yu Chen

Lyophilization of adjuvanted vaccines: Methods for formulation of a thermostable freeze-dried product

Auteur: Timothy S. Dutill, Ryan M. Kramer, Michelle Y. Chan

Cold chain and virus-free chloroplast-made booster vaccine to confer immunity against different poliovirus serotypes

Auteur: Yuhong Xiao, William C. Weldon, Steven M. Oberste, Konstantin Chumakov, Henry Daniell, Hui-Ting Chan

Prevention of pneumococcal diseases in the post-seven valent vaccine era: A European perspective

Auteur: Ron Dagan, Lorenzo Mantovani, Catherine Weil-Olivier, Mark van der Linden, Iris de Schutter

Vaccine against tuberculosis: what’s new?

Auteur: Carlotta Montagnani, Elena Chiappini, Luisa Galli, Maurizio de Martino

Technical development of a new meningococcal conjugate vaccine

Auteur: Subhash V. Kapre, Che-Hung Lee, Jean-Marie Préaud, Carl E. Frasch

Establishing a regional network of academic centers to support decision making for new vaccine introduction in Latin America and the Caribbean: The ProVac experience

Auteur: B. Jauregui, C. Ruiz Matus, C.B. Janusz, J.K. Andrus, A. Sinha, A.D. Clark, C. Sanderson, C.M. Toscano, S. Resch

Effect of age at vaccination on rotavirus vaccine effectiveness in Bolivian infants

Auteur: Lucia H. De Oliveira, Umesh D. Parashar, Rachel M. Burke, Jacqueline E. Tate, Kimberly D. Pringle, Manish Patel

Economic impact of thermostable vaccines

Auteur: Shawn T. Brown, Diana L. Connor, Patrick T. Wedlock, Marie L. Spiker, Leila A. Haidari, Kimberly Bonner, Kate Elder, Arjun Rangarajan, Julien Potet, Delphine Hunyh, Rachel Manring, Bruce Y. Lee

Economic value of dengue vaccine in Thailand

Auteur: Mirat Shah, Shawn T. Brown, Bruce Y. Lee, Rachel R. Bailey, Diana L. Connor, Yongjua Laosiritaworn, Sarah B. Kitchen, Donald S. Burke, Kristina M. Bacon, Derek A. T. Cummings

Is the world ready for an Ebola vaccine?

Auteur: Dagna O. Constenla, Lois Privor-Dumm, William J. Moss, Bruce Y. Lee, Katherine L. O'Brien, Maria D. Knoll

Improving global access to new vaccines: Intellectual property, technology transfer, and regulatory pathways

Auteur: Sara Eve Crager

A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates

Auteur: Eva G. Rakasz, Dan T. Stinchcomb, Jorge E. Osorio, Kim L. Weisgrau, Saverio Capuano, Joanna Paykel, Claire Y.-H. Huang, Joseph N. Brewoo, Michael Royals, Ginger Young, Aurelia A. Haller, Charalambos D. Partidos, Yuping Ambuel

Meningococcal vaccines: from polysaccharide to conjugate vaccines

Auteur: C. Levy, R. Cohen

New studies of BCG: implications for tuberculosis vaccines

Auteur: C Fordham von Reyn

Evidence of reduction in HPV infection and CIN2+ after vaccine introduction in Scotland

Auteur: R. L. Cameron, Kevin G. Pollock

Assessing the potential cost-effectiveness of microneedle patches in childhood measles vaccination programs: The case for further research and development

Auteur: Paul A. Rota, Susan Y Chu, James L. Goodson, Bishwa B Adhikari, Martin I Meltzer

The use of a placebo in vaccine trials

Auteur: Brian Greenwood

Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial

Auteur: Concepción F Estívariz, M. Steven Oberste, K. Zaman, Tajul I. Bari, Mark A. Pallansch, Abhijeet Anand, William C. Weldon, James D. Heffelfinger, Howard E. Gary, Stephen P. Luby, Mohammad Yunus, Steven G. Wassilak

Peptide vaccination is superior to genetic vaccination using a recombineered bacteriophage λ subunit

Auteur: Puja Chopra, Navneet Sharma, David H. Evans, Brad S. Thomas, D. Lorne J. Tyrrell, Sandra Nishikaw, Oliver F. Bathe, Kenichi Ito, Derrick E. Rancourt

Needle-free and adjuvant-free epicutaneous boosting of pertussis immunity: Preclinical proof of concept

Auteur: Véronique Dhelft, Paul-Henri Lambert, Lucie Mondoulet, Jean Petre, Beatris Mastelic Gavillet, Hong Thai Pham, Claire-Anne Siegrist, Floriane Auderset, Pierre-Henri Benhamou, Christiane Sigrid Eberhardt

Long-term evaluation of mucosal and systemic immunity and protection conferred by different polio booster vaccines

Auteur: Henry Daniell, Yuhong Xiao

Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection?

Auteur: Arash Grakoui, Christopher M. Walker

Vaccine pipeline has grown during the past two decades with more early-stage trials from small and medium-size companies

Auteur: Thomas J. Hwang, Aaron S. Kesselheim

Intranasal immunization with dry powder vaccines

Auteur: Tania F. Bahamondez-Canas, Zhengrong Cui

A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty

Auteur: Sophie M. Andrews, Andrew J Pollard

Effects of freezing on DPT and DPT-IPV vaccines, adsorbed

Auteur: A. Bell, D. Scheifele, R. Dimayuga

Introducing cholera vaccination in Asia, Africa and Haiti: A meeting report

Auteur: Robert H. Hall, David A. Sack

Emerging vaccine technologies

Auteur: Rebecca J. Loomis, Philip R. Johnson

Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign

Auteur: Anna Lena Lopez, Ramadhan Hashim, John Clemens, Marie-Paule Kieny, Deok Ryun Kim, Asish K Mukhopadhyay, Maria Teresa Aguado, Lorenz von Seidlein, Abdul A Saleh, Kamala Thriemer, Raymond Hutubessy, Mohammad Ali, Said Mohammed Ali, Benedikt Ley, Jacqueline Deen, Godwin Enwere, Ahmed M Khatib, Thomas F Wierzba, Rita Reyburn, Mohamed Saleh Jiddawi

Factors affecting the immunogenicity and potency of tetanus toxoid: implications for the elimination of neonatal and non-neonatal tetanus as public health problems

Auteur: S. Cochi, F. van Loon, A. Galazka, V. Dietz

Assessing the potency and immunogenicity of inactivated poliovirus vaccine after exposure to freezing temperatures

Auteur: Cynthia J. Snider, Konstantin Chumakov, M. Steven Oberste, William C. Weldon, Edmond F. Maes, Marcus Estrada, Eric Stevens, Howard E. Gary Jr., Dexiang Chen, Jacqueline Fournier-Caruana, Jessica A. White, Abhijeet Anand, Diana Kouiavskaia

Data at WHO

Auteur: World Health Organization (WHO)

Presentation on Considerations for integrating COVID-19 vaccination into immunization programmes and primary health care

Auteur: UNICEF, World Health Organization (WHO)

Economic costs of Rotavirus disease and the value of vaccines

Auteur: The ROTA Council

Le vaccin antipaludique RTS,S

Auteur: World Health Organization (WHO)

The RTS,S Malaria Vaccine

Auteur: World Health Organization (WHO)

WHO SAGE roadmap on uses of COVID-19 vaccines in the context of OMICRON and substantial population immunity

Auteur: World Health Organization (WHO)

Guidance to support programmes and partners to assess and address behavioural and social drivers (BeSD) of vaccination

Auteur: Francine Ganter-Restrepo

Guidance for the implementation and evaluation of strategies to increase vaccine demand and uptake

Auteur: Lisa Menning

VIEW-hub by IVAC

Auteur: International Vaccine Access Center (IVAC)

The ROTA Council

Auteur: The ROTA Council

HPV Information Centre

Auteur: HPV Information Centre

Good practice statement on the use of variant-containing COVID-19 vaccines

Auteur: World Health Organization (WHO)

Recomendaciones provisionales para el uso de la vacuna de Valneva (‎VLA2001)‎ contra la COVID-19: orientaciones provisionales, versión inicial: 18 de agosto de 2022

Auteur: Organización Mundial de la Salud (OMS)

WHO position papers

Auteur: World Health Organization (WHO)

Bolivia - Informe Evaluación Post-introducción de Vacunas contra COVID-19 (mini cPIE)

Auteur: World Health Organization (WHO), Organización Panamericana de la Salud (OPS)

Case study: Rwanda - Monitoring Approaches_FR

Auteur: UNICEF, World Health Organization (WHO)

Case Study: Rwanda - Monitoring Approaches

Auteur: UNICEF, World Health Assembly

India - Déploiement du vaccin contre la COVID-19 et outils numériques

Auteur: Ministry of Health and Family Welfare, Government of India

RDC - Ecouter et Agir les plus vulnerables - Croix Rouge RDC

Auteur: RDC Red cross

The Gambia - Country COVID-19 Intra-Action Review (IAR) Report

Auteur: World Health Organization (WHO)

Guidance on an adapted evidence to recommendation process for National Immunization Technical Advisory Groups

Auteur: World Health Organization (WHO)

Single Dose HPV vaccine Evidence master slides

Comparison table of WHO prequalified typhoid conjugate vaccines (TCVs)

Auteur: World Health Organization (WHO)

Typhoid burden of disease and potential benefits of new typhoid conjugate vaccines (TCVs)

Auteur: The Coalition against Typhoid (CaT) and the Typhoid Vaccine Acceleration Consortium (TyVAC)

Human papillomavirus vaccines: WHO position paper (‎2022 update)‎

Auteur: World Health Organization (WHO)

Vaccins contre les papillomavirus humains: note de synthèse de l’OMS (‎mise à jour de 2022)‎

Auteur: Organisation Mondiale de la Santé (OMS)

2021-10-14 mRNA Vaccine Technologies for Global Health - AGENDA

Auteur: GVIRF Secretariat

2021-10-14 mRNA Vaccine Technologies for Global Health - VIDEO

Auteur: GVIRF Secretariat

2021-10-14 mRNA Vaccine Technologies for Global Health - PRESENTATIONS

Auteur: GVIRF Secretariat

2022-03-03 Malaria Vaccine R&D and Immunization: Lessons Learned and Considerations for Global Health Impact - AGENDA

Auteur: GVIRF Secretariat

The ebola vaccine, iatrogenic injuries, and legal liability

Auteur: Kumanan Wilson, Amir Attaran

The 2016 Vaccine Development Pipeline: A special issue from the World Health Organization Product Development for Vaccine Advisory Committee (PDVAC)

Auteur: Birgitte K. Giersing, Kayvon Modjarrad, David C. Kaslow, Jean-Marie Okwo-Bele, Vasee S. Moorthy

Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial

Auteur: P. Venugopal, Prasad S. Kulkarni, Ashish Bavdekar, Darin Zehrung, Sarah McGray, Chandrashekhar Aundhkar, Tara Miller, Padmasani Venkat Ramanan, Dhananjay Kapse, Jitendra Oswal

Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women

Auteur: Ángela MaríaRuiz-Sternberg

Recomendaciones provisionales para usar la vacuna NVX-CoV2373 de Novavax contra la COVID-19: orientaciones provisionales, actualización del 27 de septiembre de 2022

Auteur: Organización Mundial de la Salud (OMS)

Recommandations provisoires pour l’utilisation du vaccin Novavax NVX-CoV2373 contre la COVID-19, mise à jour le 27 septembre 2022

Auteur: Organisation Mondiale de la Santé (OMS)

Background document to the Vaccines and immunization for monkeypox interim guidance, 16 November 2022

Auteur: World Health Organization (WHO)

Annexes to the Vaccines and immunization for monkeypox interim guidance: grading of evidence: evidence to recommendation tables, 16 November 2022

Auteur: World Health Organization (WHO)

Recomendaciones provisionales para el uso de la vacuna mRNA-1273 de Moderna contra la COVID-19: orientación provisional: actualizadas el 18 de agosto de 2022

Auteur: Organización Mundial de la Salud (OMS)

Note de synthèse: position de l’OMS concernant les vaccins contre l’hépatite A – Octobre 2022

Auteur: Organisation Mondiale de la Santé (OMS)

WHO position paper on hepatitis A vaccines – October 2022

Auteur: World Health Organization (WHO)

Recommandations provisoires concernant l’utilisation du vaccin de Valneva (‎VLA2001)‎ contre la COVID-19 : orientations provisoires, première publication : 18 août 2022

Auteur: Organisation Mondiale de la Santé (OMS)

Recomendaciones provisionales sobre el uso de la vacuna BNT162b2 de Pfizer y BioNTech contra la COVID-19 en el marco de la Lista OMS de uso en emergencias: orientaciones provisionales

Auteur: Organización Mundial de la Salud (OMS)

World Bank Covid-19 Vaccine Deployment tracker

Auteur: World Bank

COVID-19 Vaccine Distribution: Are you ready?

Auteur: JSI

Ways Health Departments Can Help Increase COVID-19 Vaccinations

Auteur: Centers for Disease Control and Prevention (CDC)

Global Vaccination Initiative

Auteur: Rockefeller Foundation

Senegal_Rapport de la revue Inter-Action (RIA)

Auteur: World Health Organization (WHO), MoH Senegal

AFRO learning site link

Auteur: World Health Organization (WHO)

The evolution of the Meningitis Vaccine Project

Auteur: Kathleen Tiffay et al.

RDC - Rapport de la revue Inter-Action (RIA)

Auteur: UNICEF, Organisation Mondiale de la Santé (OMS)

Guinée Bissau - Rapport de la revue Inter-Action sur la vaccination COVID-19

Auteur: Banque Mondiale, Organisation Mondiale de la Santé (OMS)

Somalia - Country COVID-19 Intra-Action Review (IAR) Report

Auteur: World Health Organization (WHO)

Uganda - Country COVID-19 Intra-Action Review (IAR) Report

Auteur: World Health Organization (WHO)

Guinea Bissau - Country COVID-19 Intra-Action Review (IAR) Report

Auteur: World Health Organization (WHO), World Bank

South Sudan - Country COVID-19 Intra-Action Review (IAR) Report

Auteur: MoH South Sudan

DRC - Country COVID-19 Intra-Action Review (IAR) Report

Auteur: World Health Organization (WHO)

Niger - Rapport de la revue intra-action de la vaccination contre la COVID-19 au Niger

Auteur: World Health Organization (WHO)

Mozambique - Report: COVID-19 vaccination intra-action review

Auteur: World Health Organization (WHO)

Botswana - Country COVID-19 Intra-Action Review (IAR) Report

Auteur: World Health Organization (WHO)

Syria - Country COVID-19 Intra-Action Review (IAR) Report

Auteur: World Health Organization (WHO)

Good practice statement on the use of second booster doses for COVID 19 vaccines

Auteur: World Health Organization (WHO)

Annexes to the recommendations for use of the Valneva VLA2001 vaccine against COVID 19: grading of evidence: evidence to recommendations tables, first issued 18 August 2022

Auteur: World Health Organization (WHO)

Background to the recommendations for use of the Valneva VLA2001 vaccine against COVID 19: background document to the WHO: interim recommendations for use of the Valneva vaccine VLA2001 against COVID-19

Auteur: World Health Organization (WHO)

Interim recommendations for use of the Valneva VLA2001 vaccine against COVID 19: interim guidance, first issued 18 August 2022

Auteur: World Health Organization (WHO)

Why Gender Matters: IA2030 guide

Auteur: World Health Organization (WHO)

A guide for conducting a situation analysis of immunization programme performance

Auteur: World Health Organization (WHO)

Human-centred design for tailoring immunization programmes

Auteur: World Health Organization (WHO)

Understanding the behavioural and social drivers of vaccine uptake WHO position paper – May 2022

Auteur: World Health Organization (WHO)

Behavioural and social drivers of vaccination Tools and practical guidance for achieving high uptake

Auteur: World Health Organization (WHO)

Summary of key characteristics of WHO Prequalified Rotavirus vaccines

Auteur: World Health Organization (WHO)

Considerations for Pneumococcal Conjugate Vaccine (PCV) Product Choice

Auteur: World Health Organization (WHO)

SYSVAC: Systematic Reviews on Vaccines

Auteur: Robert Koch Institute

Gavi-supported rotavirus vaccines profiles to support country decision making

Auteur: Gavi, the Vaccine Alliance

WHO vaccine reaction rates information sheets

Auteur: World Health Organization (WHO)

Vaccine Detailed product profiles (DPPs) For Gavi-supported vaccines

Auteur: Gavi, the Vaccine Alliance

Product menu for vaccines supplied by UNICEF for Gavi, the Vaccine Alliance

Auteur: UNICEF

Highly Extensible Resource for Modeling Event-Driven Supply Chains (HERMES)

Auteur: Johns Hopkins University

Service Provision Assessment (SPA) Survey

Auteur: DHS

UN OneHealth Tool, CEA country contextualization templates

Auteur: UN InterAgency WG on Costing

Immunization Delivery Cost Catalogue (IDCC)

Auteur: Thinkwell

Vaccine-Preventable Diseases (including pipeline vaccines)

Auteur: World Health Organization (WHO)

List of WHO Prequalified Vaccines

Auteur: World Health Organization (WHO)

Vaccines and immunization for monkeypox: interim guidance, 24 August 2022

Auteur: World Health Organization (WHO)

Annexes to the recommendations for use of the CanSinoBIO Ad5-nCoV-S [‎recombinant]‎ vaccine (‎Convidecia™)‎ against COVID-19

Auteur: World Health Organization (WHO)

Interim recommendations for use of the CanSinoBIO Ad5-nCoV-S [‎recombinant]‎ vaccine (‎Convidecia™)‎ against COVID-19

Auteur: World Health Organization (WHO)

Background document on the CanSinoBIO Ad5-nCoV-S [‎recombinant]‎ vaccine (‎ConvideciaTM)‎ against COVID-19

Auteur: World Health Organization (WHO)

UNIVAC

Auteur: PAHO ProVac Initiative

Vaccine Impact Modelling Consortium (VIMC)

Auteur: Vaccine Impact Modelling Consortium

Global Health Data Exchange

Auteur: The Institute for Health Metrics and Evaluation (IHME)

Questions-réponses : les vaccins anti-COVID-19 et la grossesse

Auteur: Organisation Mondiale de la Santé (OMS)

Recommandations provisoires concernant l’utilisation du vaccin ChAdOx1-S [‎recombinant]‎ contre la COVID-19 (‎vaccin anti-COVID-19 d’AstraZeneca AZD1222 Vaxzevria™, SII COVISHIELD™)‎

Auteur: Organisation Mondiale de la Santé (OMS)

Recommandations provisoires pour l’utilisation du vaccin anti-COVID-19 inactivé BIBP développé par China National Biotec Group (‎CNBG)‎, Sinopharm

Auteur: Organisation Mondiale de la Santé (OMS)

Recommandations provisoires pour l’utilisation du vaccin anti-COVID-19 BBV152 COVAXIN® de Bharat Biotech

Auteur: Organisation Mondiale de la Santé (OMS)

Recommandations provisoires pour l’utilisation du vaccin anti-COVID-19 inactivé, CoronaVac, développé par Sinovac

Auteur: Organisation Mondiale de la Santé (OMS)

Vaccine Vial Monitor (VVM)-based vaccine management

Auteur: Umit Kartoglu

Utilizar parches de microarrays para administrar las vacunas contra el sarampión y la rubéola (16ª Conferencia TechNet)

Auteur: Mateusz Hasso-Agopsowicz

Como cambiar el tamaño de los frascos puede mejorar sus servicios de inmunización (16ª Conferencia TechNet)

Auteur: Kirstin Krudwig, Wendy Prosser

Des patchs à micro-aiguilles pour administrer les vaccins contre la rougeole et la rubéole ? (16ème Conférence TechNet)

Auteur: Mateusz Hasso-Agopsowicz

Comment le changement de taille des flacons peut améliorer vos services de vaccination (16ème Conférence TechNet)

Auteur: Kirstin Krudwig, Wendy Prosser

How, where and when are we going to use microarray patches to deliver measles and rubella vaccines? (16th TechNet Conference)

Auteur: Mateusz Hasso-Agopsowicz

How changing vial size can improve your immunization services (16th TechNet Conference)

Auteur: Kirstin Krudwig, Wendy Prosser

Findings from a healthcare worker evaluation of the COVID19 vaccine label

Auteur: Casildah Lumamba, Josephine Simwinga, PATH Living Labs, Oyugi Allela, Steve Osumba, Brenda Magula

Recommandations provisoires pour l’utilisation du vaccin Moderna (‎mRNA-1273)‎ contre la COVID-19 : orientations provisoires, mise à jour le 18 août 2022

Auteur: Organisation Mondiale de la Santé (OMS)

Note de synthèse de l’OMS sur le vaccin contre la dengue– septembre 2018

Auteur: Organisation Mondiale de la Santé (OMS)

Note de synthèse: position de l’OMS à propos des vaccins contre l’encéphalite japonaise – février 2015

Auteur: Organisation Mondiale de la Santé (OMS)

Comment lire une pastille de contrôle des vaccins (PCV)?

Auteur: Immunization Academy

Déclaration de politique générale de l'OMS : révision de la politique relative aux flacons multidoses : manipulation des flacons de vaccin multidoses entamés, Révision 2014

Auteur: Organisation Mondiale de la Santé (OMS)

Note de synthèse: position de l’OMS à propos du vaccin antipaludique – mars 2022

Auteur: Organisation Mondiale de la Santé (OMS)

Malaria vaccine: WHO position paper

Auteur: World Health Organization (WHO)

Comment appliquer la politique d'utilisation des flacons multidoses

Auteur: Immunization Academy

Pastilles de contrôle des vaccins

Auteur: Organisation Mondiale de la Santé (OMS)

Synthèse technique des données actuelles publiées sur la vaccination à dose unique contre le PVH

Auteur: Single-Dose HPV Vaccine Evaluation Consortium

Résumé général des données actuelles publiées sur la vaccination à dose unique contre le PVH

Auteur: Single-Dose HPV Vaccine Evaluation Consortium

Vaccin ChAdOx1-S [recombinant] contre la COVID-19

Auteur: Organisation Mondiale de la Santé (OMS)

Vaccin contre la COVID-19 (cellule Vero), inactivé, CoronaVac

Auteur: Organisation Mondiale de la Santé (OMS)

Recommandations provisoires pour l’utilisation du vaccin anti-COVID-19 Pfizer-BioNTech, BNT162b2, en vertu du protocole OMS d’autorisation d’utilisation d’urgence

Auteur: Organisation Mondiale de la Santé (OMS)

Background document on the Novavax (NVX-CoV2373) vaccine against COVID-19

Auteur: World Health Organization (WHO)

COVAXIN® (BBV152) – Inactivated, COVID-19 vaccine

Auteur: World Health Organization (WHO)

Annexes to the interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19 - update 27 September 2022

Auteur: World Health Organization (WHO)

Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19 - update 27 September 2022

Auteur: World Health Organization (WHO)

Interim recommendations for heterologous COVID-19 vaccine schedules

Auteur: World Health Organization (WHO)

Annexes to the interim recommendations for use of the Janssen Ad26.COV2.S vaccine

Auteur: World Health Organization (WHO)

Annexes to the recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19, updated 18 August 2022

Auteur: World Health Organization (WHO)

Annexes to the recommendations for use of the Pfizer–BioNTech vaccine BNT162b2 against COVID-19, updated 18 August 2022

Auteur: World Health Organization (WHO)

COMIRNATY® (Tozinameran), vaccin à ARNm contre la COVID-19 (nucléoside modifié)

Auteur: Organisation Mondiale de la Santé (OMS)

Vaccin Janssen contre la COVID-19(Ad26.COV2-S [recombinant])

Auteur: Organisation Mondiale de la Santé (OMS)

Stakeholder preferences for a new rotavirus vaccine candidate

Auteur: PATH

Impact and cost-effectiveness of an injectable rotavirus vaccine candidate compared to oral rotavirus vaccines

Auteur: PATH

A compelling public health value proposition for injectable next-generation rotavirus vaccines

Auteur: PATH

Global Market Study : Malaria - 2021

Auteur: World Health Organization (WHO)

Annexes to the interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19 - update 15 March 2022

Auteur: World Health Organization (WHO)

Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19 - update 15 March 2022

Auteur: World Health Organization (WHO)

Background document on the Bharat Biotech BBV152 COVAXIN® (COVID-19) vaccine

Auteur: World Health Organization (WHO)

Group B Streptococcus vaccine: full value of vaccine assessment. Financial analysis

Auteur: World Health Organization (WHO)

Full Value of Vaccine Assessment: Group B Streptococcus Vaccine - Policy and Implementation Issues

Auteur: World Health Organization (WHO)

Full Value of Vaccine Assessment: Group B Streptococcus Vaccine Executive Summary

Auteur: World Health Organization (WHO), London School of Hygiene & Tropical Medicine

Group B Streptococcus Vaccine: full value vaccine assessment

Auteur: World Health Organization (WHO), London School of Hygiene & Tropical Medicine

Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19

Auteur: World Health Organization (WHO)

Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: Grading of evidence, Evidence to recommendation tables - update 15 March 2022

Auteur: World Health Organization (WHO)

Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac - update 15 March 2022

Auteur: World Health Organization (WHO)

CDC Resource page on Janssen COVID-19 Vaccine (Johnson & Johnson)

Auteur: Centers for Disease Control and Prevention (CDC)

CDC Resource page on Moderna COVID-19 Vaccine

Auteur: Centers for Disease Control and Prevention (CDC)

Pfizer-BioNTech COVID-19 Vaccine and low dead-volume (LDV) syringes and-or needles

Auteur: Pfizer Inc.

COVID-19 Vaccine Explainer - COVID-19 Vaccine (Vero Cell), Inactivated, CoronaVac®

Auteur: World Health Organization (WHO)

Annexes to the interim recommendations for use of theChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) - update 15 March 2022

Auteur: World Health Organization (WHO)

Covid-19 Vaccine Job Aid: Why are there extra doses of vaccine in the vaccine vial?

Auteur: World Health Organization (WHO)

COVID-19 Vaccine Explainer - COVID-19 Vaccine (Vero Cell), Inactivated (Sinopharm)

Auteur: World Health Organization (WHO)

Vaccines to Prevent Meningitis: Historical Perspectives and Future Directions

Auteur: Niranjan Bhat, Anthony A. Marfin, Mark R. Alderson, Jo Anne Welsch, Katie Regan, Lauren Newhouse

Findings from a healthcare worker evaluation of the COVID19 vaccine label

Auteur: PATH Living Labs

Background document on the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm

Auteur: World Health Organization (WHO)

Annexes to the interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm - update 15 March 2022

Auteur: World Health Organization (WHO)

Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm - update 15 March 2022

Auteur: World Health Organization (WHO)

To optimize COVID-19 vaccine rollout, listen to health workers

Auteur: PATH

Living Labs Initiative Overview

Auteur: PATH

COVID-19 Vaccine Explainer - COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) - UPDATED JULY 2022

Auteur: World Health Organization (WHO)

Sample size calculator for evaluation of COVID-19 vaccine effectiveness

Auteur: World Health Organization (WHO)

Evaluation of COVID-19 vaccine effectiveness

Auteur: World Health Organization (WHO)

COVID-19 Vaccine Label: User Evaluation

Auteur: PATH

A general summary of current published evidence for single-dose HPV vaccination

Auteur: Single-Dose HPV Vaccine Evaluation Consortium

Technical synthesis of the current published evidence for single-dose HPV vaccination

Auteur: Single-Dose HPV Vaccine Evaluation Consortium

COVID-19 Vaccine Explainer - COVID-19 Vaccine Moderna (nucleoside modified), (mRNA-1273)

Auteur: World Health Organization (WHO)

Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19, updated 18 August 2022

Auteur: World Health Organization (WHO)

Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) - update 15 March 2022

Auteur: World Health Organization (WHO)

Interim recommendations for the use of the Janssen Ad26.COV2.S (‎COVID-19)‎ vaccine: interim guidance

Auteur: World Health Organization (WHO)

COVID-19 Vaccine Explainer - AstraZeneca ChAdOx1-S/nCoV-19 [recombinant]

Auteur: World Health Organization (WHO)

The COVID-19 candidate vaccine landscape and tracker

Auteur: World Health Organization (WHO)

Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZeneca

Auteur: World Health Organization (WHO)

Vaccine Dose Per Container: Deciding What's Right For Your Immunization Program

Auteur: Dose Per Container Partnership

Implementing 5-dose Measles-Rubella Vaccine Vials in Zambia Research Findings

Auteur: Dose Per Container Partnership

COVID-19 Vaccine Explainer - Comirnaty (Pfizer Europe MA EEIG)

Auteur: World Health Organization (WHO)

Review of the current, public evidence on single-dose HPV vaccination

Auteur: Single-Dose HPV Vaccine Evaluation Consortium

Covid-19 vaccines: safety surveillance manual

Auteur: World Health Organization (WHO)

Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing, updated 18 August 2022

Auteur: World Health Organization (WHO)

Monitoring the cold chain: What Temperatures Should Vaccines Be?

Auteur: Immunization Academy

Administering: Using the Multi-Dose Vial Policy

Auteur: Immunization Academy

WHO Policy Statement: Multi-dose Vial Policy (MDVP)

Auteur: World Health Organization (WHO)

How to read a VVM - Infographic

Auteur: World Health Organization (WHO)

Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability

Auteur: Catherine Daly

[DUPLICATE] How changing vial size can improve your immunization services (16th TechNet Conference)

Auteur: Wendy Prosser, Kirstin Krudwig

How, where and when are we going to use microarray patches to deliver measles and rubella vaccines? (16th TechNet Conference)

Auteur: Mateusz Hasso-Agopsowicz

Pneumococcal Vaccine: Handling the change in product manufacturer and presentation

Auteur: World Health Organization (WHO)

Pneumococcal Conjugate Vaccine (PCV) 4-dose vial presentations - Frequently Asked Questions (FAQs)

Auteur: Gavi, the Vaccine Alliance

Characteristics of different presentations of Pneumococcal Conjugate Vaccines

Auteur: World Health Organization (WHO)

Japanese Encephalitis Vaccines: WHO position paper

Auteur: World Health Organization (WHO)

Dengue vaccine: WHO position paper – September 2018

Auteur: World Health Organization (WHO)

Introducing 5-dose Measles-Rubella Vaccine Vials in Zambia: Research Findings

Auteur: Dose Per Container Partnership

The Effects of Dose Per Container Change in Zambia

Auteur: Dose Per Container Partnership

Vaccine Vial Monitor (VVM)-based vaccine management

Auteur: Umit Kartoglu

Review of the current published evidence for single-dose HPV vaccination

Auteur: Single-Dose HPV Vaccine Evaluation Consortium

Webinar: Integrating Drones into Immunization Supply Chains

Auteur: UNICEF, TechNet-21, VillageReach, UPDWG

freeze free type vaccine carrier

Auteur: David Gao

Frreze Free Vaccine Carrier

Auteur: Munjal Kothari

[DUPLICATE] Vaccine Dose Per Container: Deciding What's Right for Your Immunization Program

Auteur: Dose Per Container Partnership

Introducing the Measles and Measles-Rubella (MR) Vaccine Five-dose vial Presentations Facts Sheet

Auteur: UNICEF

Immunization Dose Per Container: Decision Support Resource

Auteur: Dose Per Container Partnership

Measles and Measles-Rubella (MR) Vaccine Five-dose vial Presentations Facts Sheet

Auteur: World Health Organization (WHO), UNICEF

Vaccine Preventable Diseases Surveillance Standards

Auteur: World Health Organization (WHO)

Yellow Fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data

Auteur: Tini Garske, J. Erin Staples, Rosamund F. Lewis, Olivier Ronveaux, Yellow Fever Expert Committee, Sergio Yactayo, Neil M. Ferguson, Maria D. Van Kerkhove, William Perea

Utilisation du MenAfriVac™ (vaccin contre la méningite A) en chaîne à température contrôlée (CTC) pendant les campagnes - Guide d'adaptation et guide du formateur

Auteur: World Health Organization (WHO)

Utilisation du MenAfriVac™ (vaccin contre la méningite A) en chaîne à température contrôlée (CTC) pendant les campagnes - Module de formation pour l'organisation de séances de vaccination

Auteur: World Health Organization (WHO)

Utilisation du MenAfriVac™ (vaccin contre la méningite A) en chaîne à température contrôlée (CTC) pendant les campagnes - Guide à l'intention des décideurs et des administrateurs des programmes de vaccination

Auteur: World Health Organization (WHO)

Feasibility and costs of a targeted cholera vaccination campaign in Ethiopia

Auteur: Teshome S et al.

The future control of rotavirus disease: Can live oral vaccines alone solve the rotavirus problem?

Auteur: Roger I.Glass et al.

Typhoid vaccines: WHO position paper – March 2018

Auteur: World Health Organization (WHO)

Impact and effectiveness of meningococcal vaccines: a review

Auteur: De Oliveira et al.

Development of Stabilizing Formulations of a Trivalent Inactivated Poliovirus Vaccine in a Dried State for Delivery in the NanopatchTM Microprojection Array

Auteur: YingWan et al.

Urgent challenges in implementing live attenuated influenza vaccine

Auteur: Maria Zambon, Ajit Lalvani, Wendy Barclay, Anika Singanayagam

Implementation of hepatitis B birth dose vaccination – worldwide, 2016

Auteur: Laure Dumolard et al.

Implementation research: reactive mass vaccination with single-dose oral cholera vaccine, Zambia

Auteur: Marc Poncin et al.

Immunogenicity of fractional-dose vaccine during a Yellow Fever outbreak — Preliminary report

Auteur: Steve Ahuka-Mundeke et al.

Cost of goods sold and total cost of delivery for oral and parenteral vaccine packaging formats

Auteur: Jeff Sedita et al.

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials

Auteur: Kayvon Modjarrad et al.

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

Auteur: Martin R Gaudinski et al.

A field guide to qualitative research for new vaccine introduction

Auteur: Siff Malue Nielsen et al.

The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia

Auteur: Pieter T. de Boer et al.

A thermostable messenger RNA based vaccine against rabies

Auteur: Stitz L et al.

The influence of probiotics on vaccine responses – A systematic review

Auteur: PetraZimmermann & NigelCurtis

Cost-effectiveness of dengue vaccination in ten endemic countries

Auteur: Wu Z et al.eng

Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study

Auteur: Kimberley Kavanagh et al.

Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination

Auteur: Tomonori Nochi et al.

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report

Auteur: Pierre-Stéphane Gsell et al.

Gonorrhoea vaccines: a step in the right direction

Auteur: Kate L Seib

Placebo use in vaccine trials: Recommendations of a WHO expert panel

Auteur: Kim Mulholland, Shane K. Green, Peter G. Smith, Marie-Charlotte Bouesseau, Pieter Neels, Annette Rid, Gagandeep Kang, Arthur Caplan, Punee Pitisuttithum, Abha Saxena, Rosanna Lagos, James Colgrove, Samba Cor Sarr, Abdhullah H. Baqui, Patricia Loh, Ames Dhai, Michael Selgelid, Anant Bhan, Alex John London, Rita Gomez-Diaz, Mark Sheehan, Julie Bines

A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infant

Auteur: Prasad S. Kulkarni et al.

Serum Institute’s vaccine demonstrates significant efficacy against severe rotavirus gastroenteritis

Auteur: PATH

Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization

Auteur: Hiromasa Okayasu et al.

A freeze-stable formulation for DTwP and DTaP vaccines

Auteur: Honggang Xue et al.

Target Product Profile: Measles-Rubella Microarray Patch

Auteur: IPAC Delivery Technologies Working Group

The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial

Auteur: Rouphael, N. et al.

An updated methodology to review developing-country vaccine manufacturer viability

Auteur: Nicholas Luter et al.

Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls

Auteur: Jennifer R. Verani et al.

Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial

Auteur: Mahamadou S Sissoko et al.

Vaccine Design

Auteur: Thomas et al.

There's a New Effective Vaccine to Combat Rotavirus

Auteur: Doctors Without Borders / MSF-USA

Vial usage, device dead space, vaccine wastage, and dose accuracy of intradermal delivery devices for inactivated poliovirus vaccine (IPV)

Auteur: Jarrahian et al.

Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future.

Auteur: Richard Kenney, Yotam Levin, Efrat Kochba, Ivan Hung

Usability evaluation of intradermal adapters (IDA)

Auteur: Izrail Tsals

Rotavirus Vaccine Technical Briefings (January 2017)

Auteur: International Vaccine Access Center (IVAC)

PCV Evidence Base

Auteur: International Vaccine Access Center (IVAC)

PCV Technical Briefings

Auteur: International Vaccine Access Center (IVAC)

Gap Analysis of Rotavirus Vaccine Impact Evaluations in Settings of Routine Use

Auteur: International Vaccine Access Center (IVAC)

Gap Analyses of PCV Vaccine Impact Evaluations in Settings of Routine Use

Auteur: International Vaccine Access Center (IVAC)

VIEW-hub Report

Auteur: International Vaccine Access Center (IVAC)

Development of improved vaccine cell lines against rotavirus

Auteur: Wu W et al.

Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: A randomized controlled trial in Cuba

Auteur: Nilda Alemany, Sonia Resik, Gloria Garcia, Alina Tejeda, Lai Heng Hung, Ondrej Mach, Yenisleydis Martinez, Magile Fonseca, Roland Sutter, Manuel Diaz

Microneedle patches for vaccination in developing countries

Auteur: Jaya Arya, Mark R. Prausnitz

An economic model assessing the value of microneedle patch delivery of the seasonal influenza vaccine

Auteur: Kristina M. Zapf, Bruce Y. Lee, Kathleen Marinan, Savitha Swaminathan, Bill Snyder, James J. Norman, Sarah M. Bartsch, Angela R. Wateska, Erica Jacoby, Mercy Mvundura, Darin Zehrung, Mark R. Prausnitz, Courtney Jarrahian

Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch

Auteur: Shinsaku Nakagawa, Kazuhiko Matsuo, Ying-Shu Quan, Fumio Kamiyama, Sachiko Hirobe, Ichiro Katayama, Hiroaki Azukizawa, Naoki Okada, Takaaki Hanafusa

Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque

Auteur: William C. Weldon, M. Steven Oberste, Mark R. Prausnitz, Chris Edens, Naomi C. Dybdahl-Sissoko

Measles vaccination using a microneedle patch

Auteur: Jessica Ayers, Paul A. Rota, Mark R. Prausnitz, Chris Edens, Marcus L. Collins

Cutaneous vaccination – Protective immunization is just a skin-deep step away

Auteur: Marcel B.M. Teunissen, Darin Zehrung

Effect of jet injection on infectivity of measles, mumps, and rubella vaccine in a bench model

Auteur: Melissa M. Coughlin, Rajeev Dhere, Marcus Collins, Michael Royals, Gene Saxon, Mark Papania, Courtney Jarrahian, Paul A. Rota, Darin Zehrung, Chris Cappello

Randomized clinical trial in adults and newborns in South Africa to compare the safety and immunogenicity of bacille Calmette-Guérin (BCG) vaccine administration via a disposable-syringe jet injector to conventional technique with needle and syringe

Auteur: Benjamin Kagina, Michele Van Rooyen, Darin Zehrung, Eugene Saxon, One B. Dintwe, Mark Hatherill, Jennifer Foster, Michele D. Tameris, Thomas J. Scriba, Helen Mearns, Courtney Jarrahian, Gregory Hussey, Hennie D. Geldenhuys, Laura Saganic, Kany-Kany A. Luabeya

Stability of live attenuated rotavirus vaccine with selected preservatives and primary containers

Auteur: Dexiang Chen, Chris L. McClurkan, David M. Koelle, Manjari Lal, Eugene Saxon, Courtney Jarrahian, Andrew Roehrig, Changcheng Zhu, Darin Zehrung, Nancy A. Hosken

Presentation matters: Buffers, packaging, and delivery devices for new, oral enteric vaccines for infants

Auteur: Manjari Lal, Courtney Jarrahian

Potential Cost-Effectiveness of an Influenza Vaccination Program Offering Microneedle Patch for Vaccine Delivery in Children

Auteur: Minghuan Jiang, Joyce H. S. You, Carlos Wong

Tetanus vaccination with a dissolving microneedle patch confers protective immune responses in pregnancy

Auteur: Ioanna Skountzou, Elena V. Vassilieva, E. Stein Esser, Richard W. Compans, Andrey A. Romanyuk, Mark R. Prausnitz, Joshy Jacob

Opportunities and challenges in delivering influenza vaccine by microneedle patch

Auteur: Harry F. Hullb, Darin Zehrunga, Erica Jacobya, Courtney Jarrahiana

WHO Microarray Patch (MAP) Product Development Workshop

Auteur: World Health Organization (WHO)

The immunogenicity of thin-film freeze-dried, aluminum salt-adjuvanted vaccine when exposed to different Temperatures

Auteur: Thakkar SG et al.

First-in-human safety and immunogenicity investigations of 3 adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster to adolescents with a history of IPV vaccination

Auteur: Line M. Lindgren et al.

Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis

Auteur: Alexander Domnich, Donatella Panatto, Roberto Gasparini, Joan Puig-Barberà, Daniela Amicizia , Lucia Arata

Implementing an ebola vaccine study - Sierra Leone

Auteur: Widdowson MA et al.

Improving immunization approaches to cholera

Auteur: Saha A et al.

Which JE vaccine should my country use? (module 3)

Auteur: PATH

Preferred Product Characteristics: Measles-Rubella Microarray Patch

Safety and immunogenicity of M-M-RII (combination measles-mumps-rubella vaccine) in clinical trials of healthy children conducted between 1988 and 2009.

Auteur: Kuter BJ et al.

Portable, on-demand biomolecular manufacturing

Auteur: Keith Pardee et al.

Questions and answers on the withdrawal of the CPMP Note for guidance on preclinical pharmacological and toxicological testing of vaccines

Auteur: European Medicines Agency

Seven-year efficacy of RTS,S/AS01 malaria vaccine among young African children

Auteur: George Nyangweso, David C. Kaslow, Juliana Wambua, Gregory Fegan, Ally Olotu, Philip Bejon, Marc Lievens, Kevin Marsh, Amanda Leach, Patricia Njuguna

June 2016 VIEW-hub Report on Global Introduction and Implementation

Auteur: International Vaccine Access Center (IVAC)

Thermostability of vaccines

Auteur: Michel Zaffran, Artur M. Galazka, Julie B. Milstien

An HIV vaccine: Mapping uncharted territory

Auteur: Anthony S. Fauci

Multicriteria decision analysis and core values for enhancing vaccine-related decision-making

Auteur: Michèle A. Barocchi et al.

Rotavirus serum IgA immune response in children receiving rotarix(R) co-administered with bOPV or IPV

Auteur: Sasirekha et al., Ramani

Long-term protective effects of hepatitis A vaccines. A systematic review

Auteur: Ott J et al.

Plant-made oral vaccines against human infectious diseases—Are we there yet?

Auteur: Hui-Ting Chan et al.

Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies

Auteur: Kumru OS et al.

Antibody secreting cell responses following vaccination with bivalent oral cholera vaccine among Haitian adults

Auteur: Wilfredo R. Matias et al.

Biological challenges to effective vaccines in the developing world

Auteur: Nicholas C. Grassly et al.

Safety and immunogenicity of novel adenovirus type 26– and modified vaccinia Ankara–vectored ebola Vaccines

Auteur: Iain D. Milligan et al.

Progress in introduction of pneumococcal conjugate vaccine — worldwide, 2000–2012

Auteur: Centers for Disease Control and Prevention (CDC)

Identifying optimal vaccination strategies for serogroup A Neisseria Meningitidis Conjugate vaccine in the African meningitis belt

Auteur: Sara Tartof et al.

13-Valent pneumo vaccine (PCV13) in children partially immunized with 7-valent pneumo vaccine

Auteur: Sven Arne Silfverdal et al.

Evaluation of immune responses to an oral typhoid vaccine, Ty21a, in children from 2 to 5 years of age in Bangladesh

Auteur: Taufiqur R. Bhuiyan et al.

ffectiveness of rotavirus vaccine against hospitalized rotavirus diarrhea: A case–control study

Auteur: Maria Y.T. Ichihara et al.

Hepatitis E vaccine: WHO position paper, May 2015 - Recommendations.

Auteur: World Health Organization (WHO)

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

Auteur: Tameris MD et al.

Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by tdap brand

Auteur: Koepke R et al.

Cholera vaccine: New preventive tool for endemic countries

Auteur: Verma et al.

Malaria vaccine: WHO position paper (and summary of key points) – January 2016

Auteur: World Health Organization (WHO)

A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus

Auteur: Ming Xia et al.

Clinical experience with the meningococcal B vaccine, Bexsero®: Prospects for reducing the burden of meningococcal serogroup B disease

Auteur: David P. J. Turnerb, Philip S. Watsona

Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction

Auteur: Collette Abbott, Benjamin Tiede, George Armah, Adel Mahmoud

Smallpox vaccines: targets of protective immunity

Auteur: Bernard Moss

Analysis of safety data in children after receiving two doses of ProQuad® (MMRV)

Auteur: Stephanie O. Klopfer et al.

Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models

Auteur: Melissa A Penny et al.

Microneedle technology for immunisation: Perception, acceptability and suitability for paediatric use.

Auteur: Laura J. Sahm, Sarah Marshall, Anne C. Moore

Varicella and herpes zoster vaccines: WHO position paper, June 2014 - Recommendations.

Auteur: World Health Organization (WHO)

Comparative effects of carrier proteins on vaccine-induced immune response

Auteur: Markus Knuf et al.

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo

Auteur: Milagritos D Tapia et al.

Vaccine design reaches the atomic level

Auteur: Peter D. Kwong, Lawrence Shapiro

Report of the Immunization and Vaccines related Implementation Research (IVIR), Advisory Committee Meeting

Auteur: World Health Organization (WHO)

Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans

Auteur: Samba O. Sow et al.

Vaccine production, distribution, access, and uptake

Auteur: Jon Smith et al.

Commercially available molecular tests for human papillomaviruses (HPV): 2015 update

Auteur: Katja Seme, Anja Oštrbenk, Boštjan J. Kocjan, Mario Poljak

Parental Attitudes and Beliefs Regarding the Nine-Valent Human Papillomavirus Vaccine.

Auteur: Holly B. Fontenot, Gregory D. Zimet, Vanessa Domush

Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety.

Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers

Auteur: Subhashini Chandrasekharan et al.

Structural damages in adsorbed vaccines affected by freezing

Auteur: Wiesław Kurzątkowski et al.

Stabilization of vaccines and antibiotics in silk and eliminating the cold chain

Auteur: Jeney Zhang et al.

From empiricism to rational design: a personal perspective of the evolution of vaccine development

Auteur: Ennio De Gregorio

Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants

Auteur: Verdijk P et al.

Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles

Auteur: Srivastava A et al.

Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review

Auteur: Kaufmann SH et al.

Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique

Auteur: Joseph J. Campo et al.

Tuberculosis vaccines – rethinking the current paradigm

Auteur: Joshua S. Woodworth, Peter Andersen

Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine

Auteur: Krawczyk A et al.

Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014 — United States

Auteur: Shannon Stokley et al.

Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial

Auteur: Lee-Jah Chang et al.

Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study

Auteur: Jorge E Osorio et al.

What can rotavirus vaccines teach us about rotavirus?

Auteur: Carl D. Kirkwood, Jim P. Buttery

Modelling the cost-effectiveness of a new infant vaccine to prevent tuberculosis disease in children in South Africa

Auteur: Liezl Channing

Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality

Auteur: Helle Bossen Konradsen, Daniel M. Weinberger, Palle Valentiner-Branth, Tine Dalby, Kåre Mølbak, Hans Christian Slotved, Zitta Barrella Harboe, Camilla H. Suppli, Thomas Benfield

Dengue vaccines: Dawning at last?

Auteur: Annelies Wilder-Smith

Development of a novel malarial vaccine design – A hypothetical approach

Auteur: Subathra Devi C et al.

Is Canada patent deal obstructing Ebola vaccine development?

Auteur: Jason W. Nickerson, Amir Attaran

HPV vaccination: for women of all ages?

Auteur: Kathleen M. Schmeler, Philip E. Castle

Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination

Auteur: Stan L. Block et al.

Evidence base for new vaccine introduction in Latin America and the Caribbean

Auteur: Damian G. Walker, Jon K. Andrus

A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy

Auteur: Manish Patel et al.

The state-of-the-art of approved and under-development cholera vaccines

Auteur: M. Pastor et al.

Ebola and Marburg vaccines for Africa: one step closer

Auteur: Saranya Sridhar

New HPV vaccine provides wider protection

Auteur: Anita Slomski

Hepatitis E vaccine effective for 4.5 years

Auteur: Anita Slomski

Workshop report: Malaria vaccine development in Europe–preparing for the future

Auteur: Nicola K. Viebig et al.

WHO guidance note: Vaccine diluents, revision 2015

Auteur: World Health Organization (WHO)

EV71 vaccine: protection from a previously neglected disease

Auteur: Steve M. Graham, Nigel W. Crawford

Comparing safety & immunogenicity of TB vaccine MVA85A through intramuscular and intradermal routes

Auteur: Meyer J et al.

Alternative delivery of a thermostable inactivated polio vaccine

Auteur: Kraan H et al.

Towards ambient temperature-stable vaccines

Auteur: Schlehuber LD et al.

Rabies vaccine preserved by vaporization is thermostable and immunogenic

Auteur: Todd G. Smith et al.

The economic value of a visceral leishmaniasis vaccine in Bihar state, India

Auteur: Lee BY et al.

Prevention of pneumococcal infection with vaccines

Auteur: Eugene D. Shapiro

The access to medicine index 2014

Accelerating vaccine development and deployment

Auteur: Migena Bregu et al.

Recommended composition of influenza virus vaccines for use in the 2016 southern hemisphere influenza season

Auteur: World Health Organization (WHO)

Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis

Auteur: Michael T Osterholm et al.

Neonatal exposure to Thimerosal from vaccines and child development in the first 3 years of life

Auteur: Mrozek-Budzyn D et al.

Assessment of safety and immunogenicity of two different lots of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine manufactured using small and large scale manufacturing process

Auteur: Sharma HJ et al.

Japanese Encephalitis Vaccines: WHO position paper, February 2015 - Recommendations

Auteur: World Health Organization (WHO)

New developments in dry powder pulmonary vaccine delivery

Auteur: Sou T et al.

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

Auteur: Selidji Todagbe Agnandji et al.

Research agenda for malaria eradication: Vaccines

Auteur: The malERA Consultative Group on Vaccines

Dengue vaccines regulatory pathways

Auteur: Richard Mahoney et al.

The use of propolis as vaccine's adjuvant

Auteur: El Sayed H. El Ashry

Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine

Auteur: Roland W Sutter et al.

Is vaccine the magic bullet for malaria elimination? A reality check

Auteur: Roma Chilengicorresponding and Jesse Gitaka

Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine

Auteur: Myron M Levine

The twenty-year story of a plant-based vaccine against Hep B: stagnation or promising prospect?

Auteur: Pniewski T

WHO Working Group on technical specifications for manufacture and evaluation of dengue vaccines

Auteur: Trent D et al.

Low Cost Tuberculosis vaccine antigens in capsules: expression in chloroplasts

Auteur: Priya Saikumar Lakshmi et al.

Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial

Auteur: Feng-Cai Zhu

Assessment of the RTS,S/AS01 malaria vaccine

Auteur: VS Moorthy et al.

HPV vaccination—reaping the rewards of the appliance of science

Auteur: Simon Barton et al

A polymer/oil based nanovaccine as a single-dose immunization approach

Auteur: Sara Vicente et al.

Trend of human rabies prophylaxis in developing countries: Toward optimal rabies immunization

Auteur: Nitipong Permpalung et al.

The expanding vaccine development pipeline, 1995–2008

Auteur: Matthew M. Davis et al.

WHO policy development processes for a new vaccine: case study of malaria vaccines

Auteur: Julie Milstien et al.

Malaria vaccine research and development: the role of the WHO MALVAC committee

Auteur: Geoffrey AT Targett

Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia

Auteur: et al., Zulfiqar A. Bhutta

Vaccine R&D: Past performance is no guide to the future

Auteur: Peter Stephens

Vaccine Presentation Assessment Tool: Analytical approach and user guide

Auteur: PATH

Estimating the cost of cholera-vaccine delivery from the societal point of view: A case of introduction of cholera vaccine in Bangladesh

Auteur: Jahangir A.M. Khan, Iqbal Ansary Khan, Firdausi Qadri, Abdur Razzaque Sarker, John David Clemens, Ashraful Islam Khan, Alejandro Cravioto, Fahima Chowdhury, Ziaul Islam, Amit Saha

The value of childhood combination vaccines: From beliefs to evidence

Auteur: Khaled Maman et al.

1885, the first rabies vaccination in humans

Auteur: Rino Rappuoli

Profiling the host response to malaria vaccination and malaria challenge

Auteur: Susanna Dunachie et al.

Brazilian meningococcal C conjugate vaccine: Scaling up studies

Auteur: Renata Chagas Bastos et al.

A cluster randomized non-inferiority field trial on the immunogenicity and safety of tetanus toxoid vaccine kept in controlled temperature chain compared to cold chain

Auteur: Rebecca F. Grais, Primitive Gakima, Paul Baoundoh, Mbaihol Tamadji, Martha H. Roper, Florence Fermon, Céline Langendorf, Camille Domicent, Aitana Juan-Giner, Simona Zipursky

Use of MenAfriVac™ (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns : training module for organizing immunization sessions

Auteur: World Health Organization (WHO)

Use of MenAfriVac™ (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns: guidance for immunization programme decision-makers and managers

Auteur: World Health Organization (WHO)

The impact of heptavalent PCV on the incidence of childhood community-acquired pneumonia & bacteriologically confirmed pneumococcal pneumonia in Japan

Auteur: S. Naito et al.

Designing vaccines for developing-country populations: ideal attributes, delivery devices, and presentation formats

Auteur: Debra Kristensen, Michel Zaffran

Impact of the 13-valent pneumococcal conjugate vaccine on the incidence of pneumococcal meningitis in children

Auteur: François Dubos, Marion Lagrée, Frederic Wallet, Olivier Guilluy, A. G. Chapoutot, Rodrigue Dessein, Alain Martinot, Emmanuelle Varon

Imperfect vaccination can enhance the transmission of highly virulent pathogens

Auteur: Lorraine P. Smith, Andrew F. Read, David A. Kennedy, Susan J. Baigent, Stephen W. Walkden-Brown, Claire Powers, Venugopal K. Nair, Lydia B. Kgosana, Luke Blackwell

Efficacy and long-term safety of a dengue vaccine in regions of endemic disease

Auteur: Sri Rezeki Hadinegoro et al.

Invasive pneumococcal disease following the introduction of 13-valent conjugate vaccine in children in New York city from 2007 to 2012

Auteur: Kevin J. Konty, Jane R. Zucker, Geetha V. Nattanmai, Andrea C. Farnham, Sherly Jose, Christopher M. Zimmerman, Jennifer B. Rosen, Vikki Papadouka

Vaccins et dispositifs d'administration

Vaccins et dispositifs d'administration

Thèmes

Du Centre de connaissances

Du blog

Messages de forum récents

Membres de Technet-21

Événements à venir

Offres d'emploi

About

Knowledge Hub

Community

More